dc.contributor.author | Knapskog, Anne Brita | |
dc.contributor.author | Aksnes, Mari | |
dc.contributor.author | Edwin, Trine Holt | |
dc.contributor.author | Ueland, Per Magne | |
dc.contributor.author | Ulvik, Arve | |
dc.contributor.author | Fang, Fei | |
dc.contributor.author | Eldholm, Rannveig Sakshaug | |
dc.contributor.author | Halaas, Nathalie Bodd | |
dc.contributor.author | Saltvedt, Ingvild Tina | |
dc.contributor.author | Giil, Lasse Melvær | |
dc.contributor.author | Watne, Leiv | |
dc.date.accessioned | 2023-08-08T09:18:44Z | |
dc.date.available | 2023-08-08T09:18:44Z | |
dc.date.created | 2023-06-22T13:30:50Z | |
dc.date.issued | 2023 | |
dc.identifier.issn | 1552-5260 | |
dc.identifier.uri | https://hdl.handle.net/11250/3082979 | |
dc.description.abstract | Introduction: The kynurenine pathway's (KP) malfunction is closely related to Alzheimer's disease (AD), for antagonistic kynurenic acid (KA) and agonistic quinolinic acid act on the N-methyl-D-aspartate receptor, a possible therapeutic target in treating AD.
Methods: In our longitudinal case–control study, KP metabolites in the cerebrospinal fluid were analyzed in 311 patients with AD and 105 cognitively unimpaired controls.
Results: Patients with AD exhibited higher concentrations of KA (β = 0.18, P < 0.01) and picolinic acid (β = 0.20, P < 0.01) than the controls. KA was positively associated with tau pathology (β = 0.29, P < 0.01), and a higher concentration of KA was associated with the slower progression of dementia.
Discussion: The higher concentrations of neuroprotective metabolites KA and picolinic acid suggest that the activation of the KP's neuroprotective branch is an adaptive response in AD and may be a promising target for intervention and treatment. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Wiley | en_US |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/deed.no | * |
dc.title | Higher concentrations of kynurenic acid in CSF are associated with the slower clinical progression of Alzheimer's disease | en_US |
dc.type | Journal article | en_US |
dc.type | Peer reviewed | en_US |
dc.description.version | publishedVersion | en_US |
dc.rights.holder | Copyright 2023 the authors | en_US |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.doi | 10.1002/alz.13162 | |
dc.identifier.cristin | 2157134 | |
dc.source.journal | Alzheimer's & Dementia | en_US |
dc.identifier.citation | Alzheimer's & Dementia. 2023. | en_US |